April 11th, 2024 – Sessions
https://www.youtube.com/watch?v=f21RBKctLgg
Conference video approximate timestamps
00:04:00 Opening remarks by conference organizers
00:15:00 Lifetime achievement award: Rafael Blesa
Session 1: Pathophysiology of DSAD and ADAD
00:24:00 Lisi Flores Aguilar: Adults with Down syndrome display blood-brain barrier damage at advanced stages of Alzheimer’s disease neuropathology.
00:36:00 Agnès Pérez-Millan: Galectin-3 is upregulated and correlated with MRI findings in ADAD and genetic Frontotemporal Dementia.
00:47:00 Aina Comas Albertí: Whole blood differentially expressed genes in mutation carriers of autosomal dominant Alzheimer’s disease.
00:57:00 Marie-Claude Potier: Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome.
01:09:00 Claudio Cuello. Could the status of the NGF metabolism predict preclinical Alzheimer’s pathology in Down Syndrome?
01:23:00 Questions
Session 2: Clinical and neuropsychological presentation and non genetic modifiers of the phenotype
02:34:00 Benjamin Handen: AT(N) status and longitudinal changes in cognition in adults with Down syndrome.
02:48:00 Laura Videla Toro: Bridging the Gap: Understanding The Clinical and Cognitive Expression of Alzheimer’s Disease in Down Syndrome.
03:00:00 Jason Hassenstab: Developing a digital cognitive platform for Down syndrome-associated AD research: The ARC-DS Study.
03:17:00 Lídia Vaqué-Alcázar: Generational changes in DS: impact on intellectual disability, Alzheimer’s disease progression, and cognitive trajectories.
03:30:00 Sigan Hartley: Timing of Cognitive Decline in Down Syndrome Alzheimer’s Disease.
03:39:00 Questions
Flash talks
04:03:00 Samuel Morabito: Spatial and single-nucleus transcriptomic analysis of DSAD and sporadic AD.
04:11:00 Charlotte Jacob: Correlations between monoaminergic biomarkers, classical biomarkers and the BPSD-DSII behavioral scale in Down individuals with and without Alzheimer’s dementia.
04:17:00 Isabel Barroeta: The Down Syndrome Biobank Consortium: an initiative to advance research on Alzheimer´s disease in Down Syndrome.
04:25:00 Íñigo Rodríguez-Baz: Predominant Visuoperceptual Disfunction in a Patient with Down Syndrome associated Alzheimer’s Disease.
04:33:00 Natalie Edwards: Cerebrovascular disease and neuroinflammation enhance the classification accuracy of AD-related clinical diagnostic conversion in adults with DS.
04:39:00 Sara Gutiérrez Fernández: Molecular basis of clinical onset in familial Alzheimer’s disease (FAD).
04:45:00 Fernando Gonzalez-Ortiz: Plasma p-tau217 is a severity and progression biomarker in Niemann-Pick disease type C.
04:52:00 Charlotte Johansson: Electrophysiological biomarkers in autosomal dominant Alzheimer Disease.
04:58:00 Laura del Hoyo Soriano: Improving IQ measurement in DS by using true deviation from population norms with the Kaufman Brief Intelligence Test.
Session 3: Biomarkers 1
06:10:00 Sandra Gimenez: AD effects on sleep in adults with DS.
06:22:00 Janna Dijkstra: Clinical and fluid biomarker characteristics of ADAD in Dutch memory clinic.
06:32:00 Michael Okafor: Reducing the production of toxic Aβ peptides in Alzheimer’s disease: a new therapeutic strategy?
06:41:00 Lajos Csincsik: Retinal and Choroidal Vascular Changes as Potential Biomarkers for AD in Individuals with DS: A Cross-Sectional Study.
06:54:00 Johannes Levin: Lewy-Body co-pathology in the context of Alzheimer Disease originating in a genetic β-amyloid trigger.
07:08:00 Questions
Session 4: Biomarkers 2
07:36:00 Erik Johnson: CSF Proteomics Define the Natural History of ADAD.
07:48:00 Laia Montoliu-Gaya: Proteomic Analysis of Cerebrospinal Fluid in DS: Uncovering Shared and Distinct Pathological Alterations in Comparison to Late Onset and ADAD.
07:57:00 John Ringman: The A431E PSEN1 mutation arising as a founder effect in Jalisco State in Mexico: from clinical presentation to an animal model.
08:11:00 Lisa Vermunt: Within-individual trajectory of plasma GFAP in dominantly inherited Alzheimer disease.
08:18:00 Nicolas Barthelemy: Soluble tau phosphorylation and MTBR-tau243 changes in autosomal dominantly inherited AD. Prerecorded talk
08:30:00 Questions
April 12th, 2024 – Sessions
https://www.youtube.com/watch?v=eskABv_4n_M
Conference video approximate timestamps
Session 5: Neuroimaging
00:08:00 Brian Gordon: Comparisons of Tau PET Imaging in Down Syndrome and Autosomal Dominant AD.
00:20:00 Patrick Lao: Longitudinal changes in neuroimaging biomarkers of small vessel disease by sex and APOE genotype.
00:31:00 José Enrique Arriola Infante: Pattern of brain metabolism (FDG-PET) in individuals with DS. Association with sociodemographic variables and Alzheimer´s disease stages.
00:43:00 Alejandra Morcillo-Nieto: Medial Temporal Lobe Volumes as Biomarkers for Early Alzheimer’s Detection in in Down Syndrome.
00:57:00 Beau Ances: Cortical thickness along AD continuum in Down syndrome.
01:12:00 Questions
Session 6: Modelling (Natural history models)
01:39:00 Juan Fortea: APOE4 homozygotes: A new member of in the genetically determined AD familiy.
01:52:00 Raquel Sánchez-Valle: Cortical Asymmetry in individuals with Autosomal Dominant Alzheimer’s Disease.
01:58:00 Eric Rubenstein: A population study of Alzheimer’s dementia in Down syndrome.
02:21:00 Lucia Maure Blesa: Occurrence and description of epilepsy in adults with DS.
02:34:00 Eric McDade: DIAN.
02:44:00 Questions
Session 7: Clinical trials in presymptomatic / at risk individuals of genetic AD
03:40:00 Michael Rafii: Clinical Trials Targeting AD in DS.
03:55:00 Laurent Meijer: Phase 1 clinical study of leucettinib-21, a Dyrk1a kinase inhibitor drug aiming at the correction of cognitive disorders.
04:12:00 María Carmona-Iragui: A phase III, randomized, double-blinded study of the efficacy and safety of LEvetiracetam to prevent Seizures in Symptomatic Alzheimer’s Disease in adults with Down syndrome: the LESS-AD trial.
04:35:00 Beatriz Bosch: Autosomal Dominant Alzheimer’s Disease Barcelona Cohort.
04:43:00 André Strydom: The H21 consortium – enabling treatment trials for Alzheimer’s disease in Down syndrome.
04:57:00 Questions
Session 8: Collaboration and networking opportunities for AD research in individuals with Down syndrome and ADAD.
06:09:00 Laurie Ryan and Erika Tarver. NIH Funding Opportunities.
06:17:00 Angela Bradshaw. Collaborative engagement with patient organisations in EU-funded research.
06:30:00 Bessy Benejam. DABNI and Horizon 21 experience
06:42:00 Jason Hassenstab. DIAN experience and Multisite International R01 in DS
06:47:00 Questions
07:38:00 Panel discussion: “Ethical considerations and implications of AD research in individuals with Down syndrome and ADAD with the approval of new treatments”.
Natalie Ryan. UCL Queen Square Institute of Neurology; London, UK
Alberto Lleó. Hospital of Sant Pau; Barcelona, Spain
Ann Cohen. University of Pittsburgh; Pittsburgh, USA
Shahid Zaman. University of Cambridge; Cambridge, UK
08:40 Closing remarks and summary of conference findings by conference organizers